高脂蛋白血症患者心血管疾病的一级和二级预防(a)。

Q1 Medicine

Clinical Research in Cardiology Supplements Pub Date : 2017-03-01 DOI:10.1007/s11789-017-0090-3

P Grützmacher, B Öhm, S Szymczak, C Dorbath, M Brzoska, C Kleinert

{"title":"高脂蛋白血症患者心血管疾病的一级和二级预防(a)。","authors":"P Grützmacher, B Öhm, S Szymczak, C Dorbath, M Brzoska, C Kleinert","doi":"10.1007/s11789-017-0090-3","DOIUrl":null,"url":null,"abstract":"General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).","PeriodicalId":39208,"journal":{"name":"Clinical Research in Cardiology Supplements","volume":"12 Suppl 1","pages":"22-26"},"PeriodicalIF":0.0000,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11789-017-0090-3","citationCount":"7","resultStr":"{\"title\":\"Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).\",\"authors\":\"P Grützmacher, B Öhm, S Szymczak, C Dorbath, M Brzoska, C Kleinert\",\"doi\":\"10.1007/s11789-017-0090-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).\",\"PeriodicalId\":39208,\"journal\":{\"name\":\"Clinical Research in Cardiology Supplements\",\"volume\":\"12 Suppl 1\",\"pages\":\"22-26\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s11789-017-0090-3\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research in Cardiology Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s11789-017-0090-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11789-017-0090-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 7

摘要

一般脂蛋白(Lp) (a)筛查有助于识别心血管疾病高危患者。无创方法可以早期发现临床无症状的早期动脉粥样硬化疾病。医疗选择仍然不能令人满意。在德国，Lp(a)单采是一种成熟的治疗方法，用于进行性心血管疾病的二级预防。他汀类药物降低低密度脂蛋白胆固醇和血小板聚集抑制剂仍然是医学治疗的基础。高脂蛋白血症患者ldl -胆固醇的目标水平应该调整(a)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).

General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Research in Cardiology Supplements Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

6.10

自引率

0.00%

发文量